Tests are cheap to run. The expensive part is getting them there.
ExamplesTHYROCARELALPATHLABMETROPOLIS
How this business works
A pathology lab looks like it sells tests, but it really sells logistics. The machine that runs the test is inexpensive and fast, so the test itself costs almost nothing to execute. What costs money is collecting the blood sample, getting it to the lab before it spoils, and running enough tests through the same expensive analyser to spread its fixed cost across many patients. That one fact shapes every choice a lab makes about how to compete.
The six questions that explain this business
Answer these six and you have understood the industry. The rest of the page is the detail behind them.
Where does demand come from?
From three sources with opposite cyclicality. First, illness: steady, non-discretionary, and unchanging across economic cycles. Someone with a fever sees a doctor and gets tested, in recession or boom. Second, doctor-prescribed monitoring: recurring, but under pressure from home testing kits and fewer in-person doctor visits. Third, preventive checkups and wellness programmes: discretionary, and the first thing cut when budgets tighten or confidence wobbles. A lab heavy on preventive demand is riding a discretionary cycle and will see demand disappear in a slowdown.
Who controls the price?
Partly the lab, mostly the market. Test prices are visible online, and customers shop on price, making most tests commoditised. A lab cannot hide on price for routine tests like blood counts or glucose, and it cannot charge much more than rivals without losing volume. Radiology and specialised molecular tests hold price better because they are rare or hard to compare. Beyond that, pricing power comes from brand and trust: a doctor sending samples prefers the lab they know is reliable. But this brand value does not translate into higher prices. It mainly protects volume. The real pressure comes from new entrants willing to price below the incumbent, and from hospitals and corporate clients who use their size to negotiate discounts that can be 30-50% below retail prices.
What's the hardest thing to get?
Collection density and sample logistics. Anyone with capital can buy an analyser, but getting samples fast enough that they do not spoil requires a network of collection points close to the patient. Building that network across multiple cities takes years and upfront investment. Once built, it is hard for a rival to match. But this is a one-time advantage: a well-funded competitor with the same capital can build density too. The second hard-to-get resource is trust: doctors trust certain labs to deliver reliable results on time, and that trust is earned over years of consistent performance, not bought with money.
Where does the money disappear?
Into sample collection and overnight logistics. Every sample needs staff to collect it, cool storage to preserve it, and transport to the lab. In a dense network these costs are modest. In a sparse network they are punishing. On top of that, a lab using franchise collection centres pays 20-35% of test revenue to the franchisee, cutting the margin before the lab covers its own fixed costs. The second major leak is into B2B contract discounting: hospitals and corporate clients demand prices 40-60% below retail, and losing those contracts means losing massive volume but also the fixed cost justification, so the lab is forced to take the low prices to keep machine utilisation high. The cash also pours into new collection centres because growth requires geographic expansion, but new centres lose money until they reach critical sample volume.
What usually breaks first?
A price war followed by margin compression. Once a competitor enters a city with a new machine and lower costs, price pressure starts. The incumbent can cut prices and lose margin or hold price and lose volume. There is no good choice. This is accelerated if a large B2B customer, usually a hospital, takes the opportunity to renegotiate the contract to a lower price. A lab that depends on one or two large contracts is exposed: losing a big customer means losing thousands of daily tests and the fixed cost justification at once. The second killer is the trap many labs fell into with COVID: they built cost structures on 2021-2022 peak volumes. When COVID demand collapsed, fixed costs stayed high and margins were crushed. Any lab's recent growth that looks strong may just be recovery from the COVID spike, not new earning power.
Why can't rivals just copy it?
Accumulated collection density and doctor trust. A lab with collection points across multiple cities and years of relationships with referring doctors and hospitals has a real advantage over a new entrant: samples come in reliably, and doctors know the lab is trustworthy. But this moat is thin. It does not let a lab raise prices. It mostly prevents a new competitor from instantly taking market share, because a new entrant has to build the same density from zero. But a well-funded competitor with cheap capital can do that, and when it does, the only battleground is price. The moat protects scale, not profitability. What really matters is staying the lowest-cost operator in the market, and that is hard to sustain when all players are buying the same machines.
The question beginners always ask
If a lab is running millions of tests, why is it not enormously profitable?
Because the test itself is cheap to run. An analyser that costs ₹2 crore can run half a million tests a year, so the per-test cost of the machine is tiny. But that is only one small part of the cost. The expensive parts are the network of collection centres, the overnight logistics to keep samples fresh, the staff and training, and the commissions paid to franchise collection partners. Even at enormous scale, if each test is priced at ₹100 after discounts and commissions, and the non-machine costs are ₹40 per test, then the lab makes ₹60 per test. At five million tests a year that looks like ₹30 crore in profit, but only until a competitor cuts price to ₹80 per test and forces you to follow. Now profit falls to ₹40 per test and ₹20 crore a year, and you are back to a modest return on invested capital. Volume is not the same as pricing power, and in diagnostics, volume at low prices does not guarantee profit.
First, what is a diagnostics lab really?
Strip away the white coats and the equipment, and a lab is one simple problem: how to keep an expensive machine busy.
01
A lab is a logistics business wearing a lab coat
The test itself, the part that happens in the machine, is the cheap end of the business. A blood draw, a sample run, a result printed out. Modern analysers are fast and reliable, and the chemical reagents are commodities. What is actually expensive is everything around that one moment: the network of collection centres spread across a city, the drivers and coolers moving samples overnight to stay fresh, the staff trained to draw blood without bruising the patient, and the relationships with doctors and hospitals who send you samples day after day. Once you see that, you see why a lab with collection density across a whole city or country can beat one that does not, even if they own the exact same machine.
For exampleTwo labs buy identical analysers for the same price. The first has collection points scattered and can run only 200 tests a day through the machine. The second has dense coverage across the city and runs 800 tests a day through an identical machine. The machine costs the same, but one is sitting idle while the other is nearly full.
02
A lab's profit lives in how full its machines are
An analyser costs the same whether it runs 50 tests a day or 500. The building, the power, the technicians all have to be paid for whether the machine is humming or sitting quiet. So profit is almost entirely a question of utilisation, which is just another way of saying how busy the machine is. Spread the same fixed cost across more tests and profit climbs, almost without any extra spending. This is called operating leverage, and it is the heart of pathology economics.
For exampleRun 100 tests a day and the cost per test is high because you are spreading fixed costs thinly. Run 400 tests a day and the fixed cost is the same, but now it is spread across four times as many tests, so the per-test cost falls by roughly three-quarters. That is where the profit comes from.
03
One blood draw, many possible tests
Here is the second quiet lever: from a single blood draw, a lab can run a dozen different tests. One needle in the arm, one vial of blood. The collection cost and the transport cost are the same whether the lab runs one test or thirty. So a lab making money is really a lab that bundles tests into packages. A basic wellness screen might be ten tests from one draw. A pre-surgery screening might be fifteen. Each test shares the same logistics cost with all the others.
For exampleA patient comes in for a routine checkup. The lab draws once and runs tests for glucose, cholesterol, liver function, kidney function, blood count, and thyroid. The blood draw and transport cost are split across all six. Do it with only one test and the logistics cost per test is six times higher.
Two completely different ways to run a lab
There are only two business models that survive, and they point in opposite directions.
01
The wholesale hub-and-spoke model
Cheap tests, enormous volume, and one or two central laboratories that process everything. Samples are collected all over the country, kept cool, and flown or driven overnight to the hub. The hub does nothing but run tests at scale. This model competes on cost per test, so it wins by having the lowest prices and the biggest network. It makes money by sheer volume and machine utilisation. Margins are thin because price is the only selling point.
For exampleThyrocare collects samples from hundreds of small collection centres scattered across India, flies them all to one or two central labs overnight, and runs them at enormous scale. A test costs less, so doctors and patients choose it. The company survives because it fills its machines with millions of tests a year.
02
The retail branded model with collection presence
Own collection centres in the cities you target, build a consumer-facing brand, charge more per test, and cultivate relationships with doctors and hospitals. You compete on trust and convenience, not price. Patients recognise your brand, doctors know you deliver results on time, and you have enough local presence that samples do not spoil. Margins are higher because you have pricing power, but you have to earn it through service quality and brand.
For exampleDr Lal PathLabs and Metropolis have owned and branded collection centres in major cities. People know the name, walk in confident, and pay a bit more because they trust the quality and the convenience. Doctors send samples because they know the results are reliable.
How a lab actually makes money
Three levers pull profit in the right direction. Miss any one and margins suffer.
01
Lever one: keep the machine as full as possible
This is the operating leverage idea compressed into one sentence. More tests through the same machine equals higher profit on the same cost. A lab grows by either adding more collection centres to feed more samples to the machine, or by building a second machine once the first is saturated. The temptation is to add machines before they are needed. The discipline is to fill one machine to the brim before adding another.
For exampleA lab running at 60% capacity across five machines is losing money. The same lab running at 85% capacity across four machines is making serious money, because the fixed costs are lower and utilisation is higher.
02
Lever two: run more tests per sample
Bundle tests into packages rather than running single tests. A corporate wellness screen, a pre-surgery panel, an annual health checkup. Each package has a higher revenue per draw because one collection event is monetised across multiple tests. A lab that sells single tests is leaving money on the table because it is paying the collection and transport cost for each one separately.
For exampleSell a single glucose test for ₹100 and the sample collection cost of ₹30 is a third of revenue. Sell a ten-test package for ₹600 and the same ₹30 collection cost is just 5% of revenue. The profit per rupee collected goes up sharply.
03
Lever three: get the price right without starting a war
Price is dictated by competition and test visibility online. There is no secret to getting customers to pay a premium: they have to trust that your results are right and your turnaround is fast. Beyond that, price is mostly set by the market. Where a lab has any real pricing power is in niche, specialised tests that few competitors offer, or in packages that are hard to unbundle and compare online.
For exampleA routine blood count is visible on five websites at five different prices. A lab cannot hide on price here, so it competes on convenience or speed. But a specialised molecular test for a rare disease might have fewer competitors, so the lab can charge a bit more.
Where demand comes from, and why it changes
Not all tests behave the same. Three types of demand pull in different ways.
01
The steady, non-discretionary demand: illness
Someone feels sick, goes to a doctor, the doctor orders a test. This is real demand that does not disappear in a recession. Illness is not optional. Routine pathology tests for fever, cough, infection, or pain come in every day and every year, in good times and bad. This is the base load that keeps a lab functioning even when the economy slows.
For exampleA patient with a fever sees a doctor. The doctor orders blood and urine tests. The patient pays, the lab runs the tests. Three weeks later the economy is in recession. The fever patient still sees the doctor, still gets tested.
02
Doctor-prescribed testing: recurring but under threat
Doctors order tests as part of ongoing care: blood checks for diabetic patients every three months, monitoring tests for people on medications, regular checkups for known health conditions. These are routine and recurring, but they are under pressure from two sides. First, new technology like home testing kits and wearables are starting to bypass the lab entirely for certain tests. Second, online consultation has reduced the number of in-person doctor visits where a test gets ordered.
For exampleA diabetic patient saw a doctor in person four times a year for monitoring and got blood work each time. Now the doctor offers video consultations, and the patient does not need as many in-person checks. Tests ordered drop by a third.
03
Preventive health checks: discretionary and the first thing cut
Corporate wellness programmes, annual health checkups, preventive screening packages. These are the tests people get when they feel fine and want to stay that way. When money is tight or confidence wobbles, companies cut wellness budgets and people skip their annual checkups. In a recession, this demand vanishes fast. During booms and job growth, it is strong. A lab heavy on preventive testing is riding a discretionary cycle.
For exampleA large IT company runs employee wellness checks every year. In good times 90% of staff participate. In a downturn or a hiring freeze, participation drops to 50% because the company cuts the programme. The lab loses thousands of tests overnight.
The brutal economics of test pricing
Here is the honest truth: tests are commoditised, and that crushes margins.
01
Prices are visible online and hard to hide
A patient can search the price of a blood test on Google or a price-comparison app and see what five labs charge. The differences are not huge, because the tests are the same. A lab cannot charge three times more than a rival by claiming to be better at drawing blood. Customers see the price difference and shop. This is commoditisation in its purest form: the product is identical and transparent, so price becomes the main lever.
For exampleA lipid panel costs ₹250 at one lab and ₹350 at another. The test is identical. A price-conscious patient chooses the cheaper one. No brand loyalty, no mystique, just the number on the screen.
02
Radiology and molecular tests hold price better than routine pathology
A CT scan is expensive and not easily comparable because it depends on the quality of the machine and the radiologist reading it. A DNA test for a rare genetic condition is harder to find at every lab, so the lab has more breathing room on price. But routine blood tests, urine tests, basic counts and chemistries are everywhere. The player with the lowest cost per test can undercut and win.
For exampleA routine haemoglobin test is ₹80 everywhere. A whole-genome sequencing test is ₹15,000 at Lab A and ₹20,000 at Lab B, and some customers will pay more for one if it has a faster turnaround or a trusted brand. Price power exists where tests are rare or complex.
03
New online-first players started a price war
When digital-first diagnostics companies entered India with online ordering and home sample collection, they disrupted pricing. Traditional labs were used to charging what the market would bear. Online players undercut aggressively to grab volume. Traditional labs were forced to match prices or lose market share, squeezing their margins. The competitive price floor has fallen as a result, and it is unlikely to climb back up.
For exampleLab tests that cost ₹300 ten years ago are now ₹150 because online players forced prices down. The test itself became no cheaper to run, but the price competition did not stop when online players gained share. It kept squeezing.
Where the money actually disappears
Profit sounds simple: collect more samples, run more tests, profit climbs. It does not work that way.
01
Sample collection and overnight logistics are expensive
Getting a sample from a patient to the lab safely and in time costs real money. Sample collection centres need staff. Samples need to be kept cool. Overnight logistics via courier or flight is not free. Every collection point a lab adds means more fixed costs until that centre sends enough samples to justify itself. This is why collection density matters: dense collection means samples travel short distances and the cost per sample is lower.
For exampleA collection centre in a major city near the lab costs ₹50,000 a month to run. It sends 1,000 samples a month. The logistics cost is ₹50 per sample. A collection point two states away serves the same number of patients but needs expensive overnight courier at ₹100 a sample. The second centre costs twice as much to serve.
02
Commissions to franchise collection centres
Most labs cannot own and operate collection centres everywhere. So they franchise them: a small business owner runs the collection point on behalf of the lab, draws the samples, and the lab pays a commission, usually 20-35% of the test revenue. This is how a lab extends its network without capital expenditure. But it shrinks the margin on each test because the commission is a real cost.
For exampleA test sells for ₹300. The franchisee takes ₹80 as commission. The lab is left with ₹220 to cover its machine costs, overhead, and profit. If a rival lab owns its own collection centre and pays salaried staff, it might pay only ₹40 per test, leaving ₹260. Lower cost per test means the rival can undercut on price.
03
B2B hospital contracts and the discount trap
Hospitals send thousands of tests to pathology labs every day. A hospital is a huge customer and holds enormous negotiating power. A pathology lab chasing a hospital contract knows that turning it down means losing volume, so it discounts. Heavily. A test that sells for ₹200 retail might go for ₹80 into a hospital contract. Win the contract and volume surges, but margin collapses. Lose it and volume dries up instantly.
For exampleA hospital sends 2,000 tests a day. A lab bids ₹80 per test to win the contract. A rival lab bids ₹70 and takes it. Losing that contract means losing 2,000 tests a day and the fixed cost of those machines suddenly becomes too high. The pressure to discount never stops.
What usually breaks first
Diagnostics labs fail in predictable ways. Watch for these cracks.
01
A price war that eats the margin
Once a new competitor buys an analyser and opens in the same city, price pressure starts. The new lab has lower legacy costs, so it can afford to undercut. The incumbent lab is trapped: cut prices and margin falls, or hold price and lose volume. There is no good choice, and the only way out is to have better collection density or a stronger brand so customers do not defect to the cheaper competitor. Not every lab has that.
For exampleA lab has run the city for five years at healthy margins on routine tests. A new, well-funded online lab enters and prices routine tests at 30% below the incumbent. The incumbent cannot match without losing money, but raising prices loses customers. In two years, both labs are struggling with thin margins.
02
Losing a large B2B hospital or corporate contract
A lab that depends on one or two big contracts is running a fragile business. A hospital switches labs to get a better price or service, and thousands of daily tests vanish overnight. The lab is left with fixed costs it cannot cover. This is the underside of the discount trap: the customer who forces prices down today can take the business elsewhere tomorrow.
For exampleA lab's largest customer is a 500-bed hospital doing 3,000 tests a day at ₹90 per test. The hospital gets a better rate from a competitor and leaves. The lab loses ₹2.7 crore a year in revenue and has no way to replace it quickly.
03
COVID left deep scars
During 2020 and 2021, diagnostics labs ran unprecedented volumes. COVID tests, RT-PCR tests, antibody tests. Machines ran at full utilisation and margins were fat. When COVID demand collapsed in 2022, so did the volume. Labs that built their cost structure on COVID-era volumes suddenly had fixed costs that were too high. More importantly, the high-growth numbers on which valuations were based were really just a pandemic spike, not a new baseline. Any lab's reported growth off the 2021 or 2022 base is partly base effects and recovery, not new earning power.
For exampleA lab's revenue was ₹50 crore in 2019, ₹120 crore in 2021 on COVID surge, and ₹80 crore in 2023 after COVID demand collapsed. The three-year compound growth looks strong, but it is just a spike and recovery. The baseline earning power in 2023 is not actually that much better than 2019.
Why volume is not the same as pricing power
The most dangerous mistake: confusing scale with moat.
01
Millions of tests do not guarantee high profit
A pathology lab processing five million tests a year sounds enormous. But if each test nets ₹5 to the lab after collection costs, commissions, and discounts, then five million tests is only ₹25 crore revenue against fixed costs that might be ₹20 crore. Slim margin. Add one price war and profit turns negative. The trap is assuming that volume means safety. Volume is only safety if the price per test stays high. When competition commoditises the price, volume becomes a problem, not a solution, because you have enormous fixed costs that do not shrink if pricing drops.
For exampleLab A runs 2 million tests a year at ₹150 average realisation and earns ₹3 crore profit. Lab B, a rival, enters with a ₹120 price. Lab A cuts to ₹125 and volume stays at 2 million, but profit drops to ₹1 crore. Higher volume would make the margin pressure worse, not better, because the test price is the real constraint.
02
The moat is thin and depends on staying cheap
A pathology lab with thousands of collection points and billions in accumulated tests has built a real competitive advantage in sample density and doctor relationships. But this moat does not stop a well-funded rival from entering and undercutting on price. The moat is real, but it is thin. It prevents a lab from raising prices, which is where most moats actually protect profit. Here, the moat just allows a lab to compete on scale against others fighting on the same grounds.
For exampleThyrocare has the densest network and the most samples. But it competes on price, not brand or premium positioning. If a well-funded rival with the same machines and similar network density enters and prices 10% lower, Thyrocare cannot easily raise prices to counter because price is its whole value proposition.
The five numbers that decide the story
Every sector reduces to a demand metric, a pricing metric, an efficiency metric, a capital metric, and a risk metric. For diagnostics, these are the ones that matter.
Demand
Test volume and mix (illness, doctor-prescribed, preventive)
Pricing
Price per test (realised after discounts)
Efficiency
Machine utilisation
Capital
Collection density and network
Risk
Price war or big contract loss
The full metric set
What each number tells you, and how to read it.
Metric
Why it matters
Tests per patient or per sample
Shows how well the lab bundles tests. Higher bundling means better revenue per collection event and higher utilisation of machines.
Revenue per patient or per test collected
Proxy for realisation after discounts. Rising shows better pricing power or higher-value mix. Falling shows price war or shift to lower-margin tests.
Samples per collection centre
Shows collection density and network efficiency. Higher density means lower logistics cost per sample and better machine utilisation.
Machine utilisation percentage
The core operating leverage lever. The more tests per machine per day, the more profit per rupee of fixed investment. This is where the real margin lives.
B2B (hospital/corporate) versus B2C (retail) mix
B2B contracts carry lower margin but higher volume. B2C carries better margin but is more discretionary. The mix decides how stable earnings are.
Price per test (realised)
Actual revenue per test after all discounts and commissions. Not the list price, but what the lab actually gets paid. Falling price is the biggest red flag.
Cost per test
Fixed costs divided by test volume, plus variable costs. Tells you how much the lab needs to grow to maintain margins if price stays flat.
Return on capital
Diagnostics is capex-light compared to hospitals, but machines and collection networks are still capital. ROCE above 20% is strong; below 12% suggests overcapacity or weak pricing.
One sentence to remember
A pathology lab is a logistics business fighting to stay full and cheap. Its moat is real but thin, and it survives or fails on price.
Take these ideas further
Operating LeverageFixed Cost AbsorptionHub and SpokeCommoditisationTrust as Moat